31 results about "Growth differentiation factor" patented technology

The present invention relates to novel monoclonal anti-human-GDF-15 antibodies, pharmaceutical compositions, kits, methods and uses and the cell lines capable of producing the monoclonal antibodies described herein. The present invention further relates to novel antibodies to human GDF-15 capable of inhibiting cancer growth.

Provided are a biological material for restoring ovarian functions, a preparation method therefor and the use thereof, relating to the technical field of biological materials. A large number of experiments verify that: it is found that a specific biological protein component for reversing ovarian functions in extracellular vesicles is the growth differentiation factor 9 (GDF-9), and the mechanism of action thereof for restoring the ovary is determined, and therefore extracellular vesicles (GOEs) that overexpress GDF-9 serve as an active substance, and by means of extraction and purification of said component, the purpose of targeted therapy is achieved.

The invention relates to screening and application of a chronic kidney disease plasma protein marker, and belongs to the technical field of plasma protein markers. The protein marker combination comprises 25 proteins such as de-integrin metalloproteinase 22, keratinoin, chitosanase 3-like protein 1, an XVIII type collagen alpha 1 chain, a VI type collagen alpha 3 chain, a growth differentiation factor 15, phospholipid globulin glycan 1, a renal injury factor 1, histidine-rich calcium binding protein, kallikrein related peptidase 4 and the like which are positively correlated with the chronic kidney disease. The kit also comprises seven proteins such as a contact protein 5, an Erb-b2 receptor tyrosine kinase 3, an Erb-b2 receptor tyrosine kinase 4, an insulin-like growth factor binding protein 3 and the like which are negatively related to the chronic kidney disease. Compared with previous cross section research or case contrast research, the protein related to chronic kidney disease incidence can be screened, and the causal time sequence of the protein and chronic kidney disease is clearer.

The invention relates to the technical field of immunofluorescence detection reagents, in particular to a chemiluminescence reaction system of cerium dioxide-based alkaline phosphatase, a chemiluminescence immunodetection kit and application of the chemiluminescence reaction system and the chemiluminescence immunodetection kit. The chemical reaction system comprises coated magnetic beads and a growth differentiation factor 15 antibody containing a ceria-based alkaline phosphatase label, and the surface of each coated magnetic bead is coated with an anti-growth differentiation factor 15 antibody and streptavidin; wherein the weight m1 of the coated magnetic beads and the weight m2 of the antibody marked with the ceria-based alkaline phosphatase and used for marking the growth differentiation factor 15 meet the relational expression that m1: m2 is smaller than or equal to 400: 1. According to the chemiluminescence reaction system, ceria-based alkaline phosphatase is used for replacing traditional alkaline phosphatase, and the stability and accuracy of chemiluminescence immunodetection of the growth differentiation factor 15 can be synchronously improved.

Provided herein is a method for treating or preventing a disease or disorder associated with a deregulated NRF2 / KEAP1 pathway, comprising administering a subject in need thereof a therapeutically effective amount of entacapone or nitecapone or a pharmaceutically acceptable salt thereof; and entacapone or nitecapone can reversibly bind to KEAP1, those compounds activated NRF2 in vitro and in vivo by reversibly modifying C151 on KEAP1, and both drugs can enhance the expression of growth differentiation factor 15 (GDF15) and NRF2 downstream antioxidant response elements (ARE) genes.

Disclosed is a method for diagnosing or predicting a stage of colorectal health status in an individual, including: providing a biological fluid sample of the individual; detecting the content of a marker in the biological fluid sample; and determining the stage of the colorectal health status in the individual according to the detected content of the marker, where the biomarker is selected from: any one or more of trefoil factor 1, trefoil factor 3, insulin-like growth factor binding protein 1, insulin-like growth factor binding protein 4, serine protease inhibitor A1, osteopontin, or growth differentiation factor-15.

The present invention relates to the use of at least one plant extract capable of activating GDF11 growth factor (Growth Differentiation Factor 11) for the treatment of hair growth, and to a cosmetic or pharmaceutical composition comprising at least one extract as an active ingredient for the treatment of hair growth. The at least one extract is selected from the group consisting of: a peptide and sugar enriched extract derived from a plant cell culture of scabrous raphanus; an extract rich in peptides and sugars derived from a lotus corniculatus plant cell culture rich in somatic embryos; an aqueous ethanol extract derived from artichoke flower heads; and / or a combination of a water soluble extract derived from Opuntia ficus stem nodes and a water ethanol extract derived from coffee beans.

Described is a low voltage, pulsed electrical stimulation device for controlling expression of growth differentiation factor 10 (“GDF10”), a useful protein, by tissues. Also described are methods of enhancing expression of GDF10 in cells, particularly a method of stimulating the expression and / or release of GDF10 in a cell having a gene encoding GDF10, wherein the method includes applying a bioelectric signal produces, as measured at the level of the target cells or tissues being stimulated 2 mA to 4 mA direct current positive to the cell (e.g., directly, indirectly, or wirelessly). Applications in the treatment of cerebral strokes, brain injuries, paralysis, brain cancer, Alzheimer's disease, dementia, anxiety, Parkinson's disease, and / or essential tremors are also disclosed.

The application discloses application of growth differentiation factor 15 in preparation of products for diagnosis, prognosis and treatment of retinal arterial obstruction, and finds that serum GDF15 level of a patient with RAO is greater than or equal to 442.64 pg / mL, and is significantly positively correlated with the risk of RAO (OR=12.6), and the diagnostic accuracy can be improved by combining glucose, triglyceride and other indexes (AUC=0.922). The recombinant human GDF15 protein can inhibit ischemia and hypoxia RGC apoptosis and protect visual function. The application has important application value in early diagnosis of RAO, visual prognosis evaluation and targeted treatment.

Provided in the present invention is an antibody or fragment thereof against a human growth and differentiation factor 15 protein (GDF15). Further provided in the present invention is the use of the antibody or fragment thereof in the preparation of a drug for treating diseases or conditions. The antibody or fragment thereof provided in the present invention can bind to human GDF15 with high affinity and specificity, blocks the interaction of GDF15 with receptor GFRAL thereof, and has a longer half-life period in vivo in comparison with antibodies of the same kind.

Methods are disclosed for inhibiting posterior capsular opacification in a subject. These methods include a) selecting a subject having an eye with a lens with posterior capsular opacification or an eye with a lens at risk of developing posterior capsular opacification from a cataract surgery, and b) locally delivering to the eye of the subject a composition comprising an effective amount of growth differentiation factor 15 (GDF-15) and a pharmaceutically acceptable carrier. Pharmaceutical compositions are also disclosed that include an effective amount of GDF-15 and a pharmaceutically acceptable carrier, which are for use in inhibiting posterior capsular opacification in a subject. The pharmaceutical composition is for local delivery to the eye of the subject.

The invention belongs to the field of clinical technology, and provides preparation and clinical application of growth differentiation factor 11 (GDF11) mRNA for promoting wound healing, and the preparation method comprises the following steps: S1, carrying out N1 psi modification on GDF11 mRNA, and replacing uracil in an original sequence with N1 psi; s2, synthesizing the modified GDF11 mRNA (messenger Ribonucleic Acid); s3, purifying the synthesized GDF11 mRNA (messenger Ribonucleic Acid), so as to obtain mRNA with modified nucleoside; by optimizing the preparation method of growth differentiation factor 11 (GDF11) mRNA, the preparation method comprises the following steps: performing N1 psi modification, synthesizing by adopting a vaccinia enzyme m capping 7G capping system, adding a poly (A) tail, purifying, and wrapping in lipid nanoparticles (LNP) to form a stable delivery system, so that the stability and translation efficiency of mRNA are remarkably improved, and the stability and translation efficiency of the GDF11 are remarkably improved. And the defects existing in treatment by directly using the GDF11 protein in the prior art are overcome, an efficient and safe new strategy is provided for diabetes wound treatment, and remarkable beneficial effects are achieved.

The present application relates to the field of biomedical technology, and in particular to an application of a protein marker composition in radiation pneumonitis; the application includes using a protein marker composition above an expression level as a biomarker for radiation pneumonitis, the protein marker composition including angiopoietin-like protein 4, growth differentiation factor 15, chemokine CXC ligand, and chemokine 20; by performing cytokine chip detection and screening on peripheral blood specimens of multiple lung cancer patients undergoing chest radiotherapy before radiotherapy, it was found that high expression of angiopoietin-like protein 4, growth differentiation factor 15, chemokine CXC ligand 10, chemokine CXC ligand 13, chemokine CXC ligand 14, and chemokine 20 is a risk factor for radiation pneumonitis, and combining these cytokines can improve the prediction accuracy of radiation pneumonitis. Therefore, the above-mentioned cytokine combination may become a powerful early prediction tool for radiation pneumonitis in clinical practice.

The present invention relates to a method for assessing myocardial infarction comprising the steps of determining the amount of a first biomarker in a sample of a subject, said first biomarker being cMyBPC, determining the amount of a second biomarker in a sample of the subject, wherein said second biomarker is selected from the group consisting of: a BMP10-type peptide (Bone Morphogenic Protein 10-type peptide), FGF23 (Fibroblast growth factor 23), a BNP-type peptide (Brain natriuretic peptide type peptide), GDF-15 (Growth differentiation factor 15), ANG2 (Angiopoietin 2), CRP (C-reactive protein), ESM1 (endothelial cell specific molecule 1), or a lipid biomarker, such as Cholesterol, LDL (Low Density Lipoprotein) or APOAT (Apolipoprotein A-1) comparing the amounts of the biomarkers to references for said biomarkers and / or calculating a score for assessing myocardial infarction based on the amounts of the biomarkers, and assessing said subject based on the comparison and / or the calculation. The invention also relates to the use of a first biomarker being cMyBPC and a second biomarker selected from the group consisting of: a BMP10-type peptide, FGF23, a BNP-type peptide, GDF15, ANG2, CRP (C-reactive protein), ESM1, or a lipid biomarker, such as Cholesterol or LDL, or at least one detection agent for said first biomarker and at least one detection agent for said second biomarker for assessing myocardial infarction. Moreover, the invention further relates to a computer-implemented method for assessing myocardial infarction and a device and a kit for assessing myocardial infarction.

Provided herein are GLP1-GDF15 fusion proteins comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.

This disclosure provides combination therapy with GDF15 molecules. In some embodiments, the GDF15 molecule is a GDF15-Fc fusion, wherein a GDF15 region is fused to an Fc region, optionally via a linker. In one embodiment, the combination therapy comprises the administration of a GDF15 molecule with a GLP-1R agonist. In another embodiment, the combination therapy comprises the administration of a GDF15 molecule with a GIPR antagonist.

The invention relates to the technical field of biological medicines, in particular to application of a growth differentiation factor 11 (GDF11) in preparation of a medicine for promoting corneal endothelial injury repair. The invention reveals that the GDF11 can effectively promote the repair of corneal tissues by enhancing the proliferation activity and migration ability of corneal endothelial cells and inhibiting cell apoptosis. Based on the discovery, the invention provides a new strategy and thought for the treatment of corneal endothelial related diseases, and has important clinical application prospects.

The application discloses a composition for repairing meniscus, which comprises a growth differentiation factor and emodin, improves inflammation and oxidative stress in a microenvironment, and promotes cell chondrogenic differentiation process. It is verified that the "core-shell" co-delivery nano carrier provided by the application uses mesoporous silica nanoparticles to wrap two bioactive compounds, emodin and a growth differentiation factor, and the latter is used for promoting fibrocartilage differentiation. The dual-drug nano delivery system provides sustained release of emodin and GDF, synergistically regulates a harsh inflammatory and oxidative environment, and promotes fibrocartilage regeneration in vitro and in vivo. Benefited from this, the application also combines a three-dimensionally printed meniscus-shaped PCL frame with the composition by using a cartilage-specific matrix hydrogel, constructs a reinforced stability meniscus replacement model, has a synergistic regulation on a cartilage immune microenvironment, and realizes successful repair of a whole meniscus replacement operation of an animal (rabbit).

The embodiment of the invention discloses application of a growth differentiation factor 15 in preparation of a product for treating retinal artery occlusion. In-vitro and in-vivo experiments prove that the GDF15 has the potential of directly treating RAO: in an ischemia and hypoxia R28 cell model, the cell activity can be remarkably improved and apoptosis can be inhibited by the treatment of the recombinant human GDF15 protein. In an RAO mouse model, the GDF15 treatment can promote the survival of retinal ganglion cells and increase the thickness of a nerve fiber layer, and shows a clear eyesight protection effect. The product preferably contains recombinant human GDF15 protein, can inhibit cell death paths caused by ischemia and hypoxia in a targeted manner, and improves pathological changes such as retinal endoedema and tissue atrophy. The invention discloses the direct application of GDF15 as a therapeutic agent in RAO for the first time, provides an experimental basis for developing related drugs, and has important clinical application value in the field of ophthalmic emergency treatment.

The present invention relates to methods for detecting the presence and / or predicting the severity or stage of chronic liver fibrosis in an individual, comprising the analysis of the expression levels of at least two markers selected from the group consisting of matricellular fibrosis marker thrombospondin-2 (TSP2), insulin like growth factor binding protein 7 (IGFBP7), growth differentiation factor 15 (GDF-15), macrophage marker CD163, matricellular fibrosis markers thrombospondin-4 (TSP4) or ADAMTS9 in a biological sample obtained from said individual. The invention also relates to methods for predicting the efficacy of a treatment of a chronic liver fibrosis in an individual, comprising the analysis of said at least two markers. The invention furthermore relates to diagnostic or therapeutic test systems, comprising reagents and material that allow the analysis of said at least two markers. The diagnostic or therapeutic test system according to the present invention are suitable for use in the diagnosis of chronic liver fibrosis in an individual. The invention further relates to a composition of said at least two markers for use in the treatment of chronic liver diseases by predicting the response to treatment with a candidate agent and / or monitoring the fibrogenesis of chronic liver fibrosis under such therapy, or with, e.g., nutritional or life style intervention. The invention also relates to methods of selecting or qualifying a pharmaceutically active candidate agent or a nutritional or life style intervention for inhibiting the progression or inducing the regression of a chronic fibrotic liver disease in a patient, and a candidate agent or intervention derived from said methods.

The invention provides a GDF-15 (growth differentiation factor-15) magnetic particle chemiluminescence immunoassay quantitative detection kit, which belongs to the field of in vitro diagnosis, and comprises a magnetic particle suspension, a biotin-labeled GDF-15 capture antibody solution, an alkaline phosphatase-labeled GDF-15 detection antibody solution, a calibrator, a chemiluminescence solution and the like. The kit provided by the invention has the advantages of rapidness and simplicity in operation, high sensitivity and repeatability, large measurement range and good stability, and can make up for the defects of the existing detection method.

Provided herein are GLP1-GDF15 fusion proteins comprising a GLP1 or GLP1 variant peptide, a first linker peptide, a serum albumin protein, a second linker peptide, and a GDF15 protein.

This application pertains to antibodies or antigen binding fragments that specifically recognize Growth differentiation factor-15 (GDF15), and methods of manufacture and uses thereof.

The invention relates to the field of visual auxiliary detection, in particular to a method for detecting a growth differentiation factor 15. The method comprises the following steps: acquiring a side image of a reagent to be detected by adopting an exogenous detection mode, performing optical path analysis without interference on the reagent to be detected, determining an optical irradiation band caused by exciting light of an optical read head, and determining image reflection characteristics; and calculating a pixel discrete characterization value to label an optical irradiation band, and controlling an amplification cycle process according to a subsequent adaptive labeling result of the optical irradiation band, including obtaining reflection excitation characteristics of the optical read head at different detection heights, determining a sampling position, and evaluating whether to maintain sampling at the current detection height of the optical read head. By evaluating the optical irradiation band, the influence of media in different areas of the reagent to be detected on sampling of the optical read head is considered from the image dimension, the sampling position is adjusted, more accurate data is obtained, and the detection accuracy of the growth differentiation factor 15 is improved.

The application belongs to the technical field of antigen protein and antibody preparation and discloses a Linopneus Genomic Differentiation Factor-8 / 11 polyclonal antibody, antigen protein and a preparation method thereof. The application obtains recombinant expression of the Linopneus Genomic Differentiation Factor-8 / 11 antigen protein, obtains the Linopneus Genomic Differentiation Factor-8 / 11 polyclonal antibody after immunizing mice, and provides an advantageous tool for the research on the Linopneus Genomic Differentiation Factor-8 / 11 protein level. The application also successfully obtains a Linopneus Genomic Differentiation Factor-8 / 11 antigen protein recombinant expression vector, and can obtain the Linopneus Genomic Differentiation Factor-8 / 11 antigen protein. The application also provides a Linopneus Genomic Differentiation Factor-8 / 11 gene coding region full sequence, fills the blank of related research, and the primer pair provided by the application can amplify the above Linopneus Genomic Differentiation Factor-8 / 11 gene coding region full sequence through PCR, and can be used for other related research.

The present invention relates to methods for detecting the presence and / or predicting the severity or stage of chronic liver fibrosis in an individual, comprising the analysis of the expression levels of at least two markers selected from the group consisting of matricellular fibrosis marker thrombospondin-2 (TSP2), insulin like growth factor binding protein 7 (IGFBP7), growth differentiation factor 15 (GDF-15), macrophage marker CD163, matricellular fibrosis markers thrombospondin-4 (TSP4), ADAMTS9, ADAPT, ADAPTI, ADAPT-2, FIB-4 or Pro-C3 in a biological sample obtained from said individual. The invention also relates to methods for predicting the efficacy of a treatment of a chronic liver fibrosis in an individual, comprising the analysis of said at least two markers. The invention furthermore relates to diagnostic or therapeutic test systems, comprising reagents and material that allow the analysis of said at least two markers. The diagnostic or therapeutic test system according to the present invention are suitable for use in the diagnosis of chronic liver fibrosis in an individual. The invention further relates to a composition of said at least two markers for use in the treatment of chronic liver diseases by predicting the response to treatment with a candidate agent and / or monitoring the fibrogenesis of chronic liver fibrosis under such therapy, or with, e.g., nutritional or life style intervention. The invention also relates to methods of selecting or qualifying a pharmaceutically active candidate agent or a nutritional or life style intervention for inhibiting the progression or inducing the regression of a chronic fibrotic liver disease in a patient, and a candidate agent or intervention derived from said methods.

The subject of the present invention is to provide a method for detecting bone metastasis of cancer (excluding castration-resistant prostate cancer) with simplicity and high precision and a reagent that can be used for the aforementioned method. By measuring the amount of complete growth differentiation factor 15 (GDF15) propeptide, the amount of GDF15 propeptide fragment, or the total amount of complete GDF15 propeptide and GDF15 propeptide fragment in the specimen, bone metastasis of cancer (excluding castration-resistant prostate cancer) is detected. As the above-mentioned method for detecting bone metastasis of cancer, a method for detecting bone metastasis of prostate cancer, kidney cancer, lung cancer, breast cancer, thyroid cancer, pancreatic cancer, bladder cancer, colorectal cancer, melanoma, myeloma or lymphoma of non-castration-resistant prostate cancer is included. Furthermore, the detection reagent for bone metastasis of cancer (excluding castration-resistant prostate cancer) contains an antibody that specifically recognizes the GDF15 propeptide.

The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in the treatment of solid cancers.

The embodiment of the invention discloses an application of a growth differentiation factor 15 in preparation of a product for diagnosis, prognosis and treatment of retinal artery obstruction disease, the application finds that the serum GDF15 level of an RAO patient is greater than or equal to 442.64 pg / mL and is significantly positively correlated with the RAO disease risk (OR = 12.6), and the diagnosis accuracy (AUC = 0.922) can be improved by combining with indexes such as glucose and triglyceride. The recombinant human GDF15 protein can inhibit ischemia and hypoxia RGC apoptosis and protect the eyesight function. The invention has important application value in RAO early diagnosis, vision prognosis evaluation and targeted therapy.

To solve the problem that, to date, many cancers are still areas of unmet medical needs, and accordingly, means to more effectively treat cancer are needed.SOLUTION: The present invention relates to uses of inhibitors of human Growth and Differentiation Factor 15 (GDF-15), and to combined uses of such inhibitors with immune checkpoint blockers, in treatment of solid cancers.SELECTED DRAWING: None